# Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

> **NCT00126997** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1439 (actual)

## Conditions studied

- Mumps
- Rubella
- Measles
- Varicella

## Interventions

- **BIOLOGICAL:** Measles, Mumps, Rubella and Chickenpox (live vaccine)

## Key facts

- **NCT ID:** NCT00126997
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 1439 (ACTUAL)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126997, "Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00126997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*